Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

103 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Essential thrombocythemia vs. pre-fibrotic/early primary myelofibrosis: discrimination by laboratory and clinical data.
Schalling M, Gleiss A, Gisslinger B, Wölfler A, Buxhofer-Ausch V, Jeryczynski G, Krauth MT, Simonitsch-Klupp I, Beham-Schmid C, Thiele J, Gisslinger H. Schalling M, et al. Among authors: krauth mt. Blood Cancer J. 2017 Dec 13;7(12):643. doi: 10.1038/s41408-017-0006-y. Blood Cancer J. 2017. PMID: 29233975 Free PMC article. No abstract available.
Immunohistochemical detection of vascular endothelial growth factor (VEGF) in the bone marrow in patients with myelodysplastic syndromes: correlation between VEGF expression and the FAB category.
Wimazal F, Krauth MT, Vales A, Böhm A, Agis H, Sonneck K, Aichberger KJ, Mayerhofer M, Simonitsch-Klupp I, Müllauer L, Sperr WR, Valent P. Wimazal F, et al. Among authors: krauth mt. Leuk Lymphoma. 2006 Mar;47(3):451-60. doi: 10.1080/10428190500353083. Leuk Lymphoma. 2006. PMID: 16396768
Austrian recommendations for the management of primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis: an expert statement.
Sliwa T, Beham-Schmid C, Burgstaller S, Buxhofer-Ausch V, Gastl G, Geissler K, Krauth M, Krippl P, Lang A, Petzer A, Wöhrer S, Wölfler A, Gisslinger H. Sliwa T, et al. Wien Klin Wochenschr. 2017 May;129(9-10):293-302. doi: 10.1007/s00508-016-1120-8. Epub 2016 Dec 13. Wien Klin Wochenschr. 2017. PMID: 27966016
Pre-fibrotic/early primary myelofibrosis vs. WHO-defined essential thrombocythemia: The impact of minor clinical diagnostic criteria on the outcome of the disease.
Jeryczynski G, Thiele J, Gisslinger B, Wölfler A, Schalling M, Gleiß A, Burgstaller S, Buxhofer-Ausch V, Sliwa T, Schlögl E, Geissler K, Krauth MT, Nader A, Vesely M, Simonitsch-Klupp I, Müllauer L, Beham-Schmid C, Gisslinger H. Jeryczynski G, et al. Among authors: krauth mt. Am J Hematol. 2017 Sep;92(9):885-891. doi: 10.1002/ajh.24788. Epub 2017 Jun 9. Am J Hematol. 2017. PMID: 28543356 Free article. Clinical Trial.
Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy.
Porpaczy E, Tripolt S, Hoelbl-Kovacic A, Gisslinger B, Bago-Horvath Z, Casanova-Hevia E, Clappier E, Decker T, Fajmann S, Fux DA, Greiner G, Gueltekin S, Heller G, Herkner H, Hoermann G, Kiladjian JJ, Kolbe T, Kornauth C, Krauth MT, Kralovics R, Muellauer L, Mueller M, Prchal-Murphy M, Putz EM, Raffoux E, Schiefer AI, Schmetterer K, Schneckenleithner C, Simonitsch-Klupp I, Skrabs C, Sperr WR, Staber PB, Strobl B, Valent P, Jaeger U, Gisslinger H, Sexl V. Porpaczy E, et al. Among authors: krauth mt. Blood. 2018 Aug 16;132(7):694-706. doi: 10.1182/blood-2017-10-810739. Epub 2018 Jun 14. Blood. 2018. PMID: 29907599 Free PMC article.
103 results